Bispecific Antibodies and Immune Checkpoint Modulators

The rate at which the bispecific and immune checkpoint modulator landscapes are expanding is both promising and not without challenges; having access to this accurate and comprehensive information is paramount to informed decision-making.

To conclude our landscape review series, and to explore the array of data available across the bispecific and checkpoint landscapes, our research experts explored the drug and trial report data across both modalities and provided further exclusive insights. Key aspects explored included:

A mid-year review of the drug landscape, discussing the 2000+ and 1700+ drugs respectively documented on Beacon

An exploration of the current trial landscape, including all newly identified studies within H1 2023

Insights into the effect of emerging trends and what we can expect in the future